BML-280
- Availability: 24/48H Stock Items & 2 to 6 Weeks non Stock Items.
- Dry Ice Shipment: No


BML-280
Description :
BML-280 (VU0285655-1) is a potent and selective phospholipase D2 (PLD2) inhibitor. BML-280 has the ability to prevent caspase-3 cleavage and reduction in cell viability induced by high glucose. BML-280 can be used for rheumatoid arthritis research[1][2].Product Name Alternative :
VU0285655-1UNSPSC :
12352005Target :
Interleukin Related; Phospholipase; TNF ReceptorType :
Reference compoundRelated Pathways :
Apoptosis; Immunology/Inflammation; Metabolic Enzyme/ProteaseApplications :
Metabolism-sugar/lipid metabolismField of Research :
Cancer; Metabolic Disease; Inflammation/ImmunologyAssay Protocol :
https://www.medchemexpress.com/bml-280.htmlPurity :
99.64Solubility :
DMSO : 125 mg/mL (ultrasonic)Smiles :
O=C(C1=CC2=CC=CC=C2N=C1)NCCN(CC3)CCC3(N(C4=CC=CC=C4)CN5)C5=OMolecular Formula :
C25H27N5O2Molecular Weight :
429.51References & Citations :
[1]Burkhardt U, et al. Role of phospholipases D1 and 2 in astroglial proliferation: effects of specific inhibitors and genetic deletion. Eur J Pharmacol. 2015 Aug 15;761:398-404. |[2]Tenconi PE, et al. High glucose-induced phospholipase D activity in retinal pigment epithelium cells: New insights into the molecular mechanisms of diabetic retinopathy. Exp Eye Res. 2019 Jul;184:243-257.|[3]Tsai YR, et al. Inhibition of formyl peptide-stimulated phospholipase D activation by Fal-002-2 via blockade of the Arf6, RhoA and protein kinase C signaling pathways in rat neutrophils. Naunyn Schmiedebergs Arch Pharmacol. 2013 Jun;386 (6) :507-19.Shipping Conditions :
Blue IceStorage Conditions :
-20°C, 3 years (Powder)Scientific Category :
Reference compound1Clinical Information :
No Development ReportedIsoform :
IL-1; IL-8; PLD; TNFRSF5/CD40CAS Number :
[1158347-73-9]

